Literature DB >> 6725552

Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.

A de Agostini, H R Lijnen, R A Pixley, R W Colman, M Schapira.   

Abstract

To define the factors responsible for the inactivation of the active fragment derived from Factor XII (Factor XIIf ) in plasma, we studied the inactivation kinetics of Factor XIIf in various purified and plasma mixtures. We also analyzed the formation of 125I-Factor XIIf -inhibitor complexes by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). In purified systems, the bimolecular rate constants for the reactions of Factor XIIf with C-1-inhibitor, alpha 2-antiplasmin, and antithrombin III were 18.5, 0.91, and 0.32 X 10(4) M-1 min-1, respectively. Furthermore, SDS-PAGE analysis revealed that 1:1 stoichiometric complexes were formed between 125I-Factor XIIf and each of these three inhibitors. In contrast, kinetic and SDS-PAGE studies indicated that Factor XIIf did not react with alpha 1-antitrypsin or alpha 2-macroglobulin. The inactivation rate constant of Factor XIIf by prekallikrein-deficient plasma was 14.4 X 10(-2) min-1, a value that was essentially identical to the value predicted from the studies in purified systems (15.5 X 10(-2) min-1). This constant was reduced to 1.8 X 10(-2) min-1 when Factor XIIf was inactivated by prekallikrein-deficient plasma that had been immunodepleted (less than 5%) of C-1-inhibitor. In addition, after inactivation in normal plasma, 74% of the active 125I-Factor XIIf was found to form a complex with C-1-inhibitor, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and antithrombin III. Furthermore, 42% of the labeled enzyme was still complexed with C-1-inhibitor when 125I-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional C-1-inhibitor. This study quantitatively demonstrates the dominant role of C-1-inhibitor in the inactivation of Factor XIIf in the plasma milieu.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6725552      PMCID: PMC437064          DOI: 10.1172/JCI111360

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE.

Authors:  V H DONALDSON; R R EVANS
Journal:  Am J Med       Date:  1963-07       Impact factor: 4.965

2.  The relationship of structure and function in human Hageman factor. The association of enzymatic and binding activities with separate regions of the molecule.

Authors:  S D Revak; C G Cochrane
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

3.  Structural changes accompanying enzymatic activation of human Hageman factor.

Authors:  S D Revak; C G Cochrane; A R Johnston; T E Hugli
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808

4.  Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation.

Authors:  A D Schreiber; A P Kaplan; K F Austen
Journal:  J Clin Invest       Date:  1973-06       Impact factor: 14.808

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  A pre-albumin activator of prekallikrein.

Authors:  A P Kaplan; K F Austen
Journal:  J Immunol       Date:  1970-10       Impact factor: 5.422

7.  Inhibition of activated factor XII by antithrombin-heparin cofactor.

Authors:  N Stead; A P Kaplan; R D Rosenberg
Journal:  J Biol Chem       Date:  1976-11-10       Impact factor: 5.157

8.  The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent.

Authors:  A E Bolton; W M Hunter
Journal:  Biochem J       Date:  1973-07       Impact factor: 3.857

9.  A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.

Authors:  A P Kaplan; K F Austen
Journal:  J Exp Med       Date:  1971-04-01       Impact factor: 14.307

10.  Mechanisms of activation of C'1 esterase in hereditary angioneurotic edema plasma in vitro.

Authors:  V H Donaldson
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

View more
  42 in total

1.  Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.

Authors:  L Bergamaschini; S Canziani; B Bottasso; M Cugno; P Braidotti; A Agostoni
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

2.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

Review 3.  FXII.

Authors:  G Fuhrer; M J Gallimore; W Heller; H E Hoffmeister
Journal:  Blut       Date:  1990-11

4.  Amidolytic, procoagulant, and activation-suppressing proteins produced by contact activation of blood factor XII in buffer solution.

Authors:  Avantika Golas; Chyi-Huey Joshua Yeh; Christopher A Siedlecki; Erwin A Vogler
Journal:  Biomaterials       Date:  2011-09-28       Impact factor: 12.479

5.  New insight into the effects of heparinoids on complement inhibition by C1-inhibitor.

Authors:  F Poppelaars; J Damman; E L de Vrij; J G M Burgerhof; J Saye; M R Daha; H G Leuvenink; M E Uknis; M A J Seelen
Journal:  Clin Exp Immunol       Date:  2016-04-13       Impact factor: 4.330

6.  Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency.

Authors:  M van Geffen; M Cugno; P Lap; A Loof; M Cicardi; W van Heerde
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

Review 7.  C1 inhibitor: biologic activities that are independent of protease inhibition.

Authors:  Alvin E Davis; Shenghe Cai; Dongxu Liu
Journal:  Immunobiology       Date:  2006-12-11       Impact factor: 3.144

Review 8.  Autoantibodies in angioneurotic edema.

Authors:  A E Ahmed; J B Peter; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 9.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

10.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.